Brian D. Lehmann, PhD
Dr. Brian D. Lehmann is a Research Assistant Professor of Biochemistry at the Vanderbilt School of Medicine. Dr. Lehmann’s research expertise lies at the intersection of cancer biology and bioinformatics. His unique understanding of both has led to the successful characterization of distinct molecular subgroups for triple-negative breast cancer (TNBC). These transcriptional subtypes display unique biology and sensitivity to standard chemotherapy and targeted therapies. Dr. Lehmann has advanced our understanding of androgen receptor signaling in breast cancer and is translating these discoveries to the clinic with collaborators in multi-institutional clinical trials. Together with colleagues, he has developed a novel population-based rearrangement algorithm and identified the targetable oncogenic fusions in FGFR3 and MERTK in TNBC. Dr. Lehmann’s current research focuses on alterations that promote tumor cell escape from immune surveillance and promote immune suppression.